Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7000-7006

  Nelson, Brian C ^a   Eiras, Daniel P ^b   Gomez Simmonds, Angela ^a   Loo, Angela S ^b   Satlin, Michael J ^b   Jenkins, Stephen G ^b   Whittier, Susan ^a   Calfee, David P ^b   Furuya, E Yoko ^a   Kubin, Christine J ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; MEROPENEM; POLYMYXIN B; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVOR; TREATMENT DURATION; TREATMENT OUTCOME; DRUG EFFECTS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMYXIN B; RETROSPECTIVE STUDIES;

EID: 84946239353     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00844-15     Document Type: Article

References (31)

1. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. 2012. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 18:439-448. http://dx.doi.org/10.1111/j.1469-0691.2012.03823.x.
2. Patel G, Bonomo RA 2013. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 4:48. http://dx.doi.org/10.3389/fmicb.2013.00048.
3. Patel G, Huprikar S, Factor S.H., Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099-1106. http://dx.doi.org/10.1086/592412.
4. Peña C., Suarez C, Gozalo M., Murillas J, Almirante B, Pomar V., Aguilar M, Granados A, Calbo E., Rodriguez-Bano J, Rodriguez F, Tubau F., Martinez-Martinez L, Oliver A. 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56: 1265-1272. http://dx.doi.org/10.1128/AAC.05991-11.
5. Petrosillo N, Giannella M, Lewis R., Viale P. 2013. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 11:159-177. http://dx.doi.org/10.1586/eri.12.162.
6. Li J, Nation RL, Turnidge J.D., Milne RW, Coulthard K, Rayner CR, Paterson DL 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
7. Zavascki AP, Goldani LZ, Li J, Nation RL 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357.
8. Tam VH, Schilling AN, Vo G, Kabbara S., Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3624-3630. http://dx.doi.org/10.1128/AAC.49.9.3624-3630.2005.
9. Sandri AM, Landersdorfer CB, Jacob J, Boniatti M.M., Dalarosa MG, Falci DR, Behle TF, Bordinhao R.C., Wang J., Forrest A, Nation RL, Li J, Zavascki AP 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
10. Sandri AM, Landersdorfer CB, Jacob J, Boniatti M.M., Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J., Forrest A, Nation RL, Zavascki A.P., Li J. 2013. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. JAntimicrob Chemother 68:674-677. http://dx.doi.org/10.1093/jac/dks437.
11. Zavascki AP, Goldani LZ, Cao G, Superti S.V., Lutz L., Barth AL, Ramos F, Boniatti MM, Nation R.L., Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. http://dx.doi.org/10.1086/592577.
12. Dalfino L, Puntillo F, Mosca A., Monno R, Spada ML, Coppolecchia S, Miragliotta G., Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? Apreliminary study. Clin Infect Dis 54:1720-1726. http://dx.doi.org/10.1093/cid/cis286.
13. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou V.G., Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D., Michalopoulos A. 2010. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35:194-199. http://dx.doi.org/10.1016/j.ijantimicag.2009.10.005.
14. Vicari G, Bauer SR, Neuner E.A., Lam SW. 2013. Association between colistin dose and microbiologic outcomes in patients with multidrugresistant gram-negative bacteremia. Clin Infect Dis 56:398-404. http://dx.doi.org/10.1093/cid/cis909.
15. Kassamali Z, Danziger L. 2014. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Pharmacotherapy http://dx.doi.org/10.1002/phar.1510.
16. Elias LS, Konzen D, Krebs J.M., Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231-2237. http://dx.doi.org/10.1093/jac/dkq285.
17. Bellomo R, Ronco C, Kellum J.A., Mehta RL, Palevsky P. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
18. Charlson ME, Pompei P, Ales K.L., MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
19. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas J.M., Goossens H., Mulazimoglu L, Trenholme G, Klugman K.P., Bonomo RA, Rice LB, Wagener MM, McCormack J.G., Yu VL. 2004. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 140:26-32. http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00008.
20. Bone RC, Balk RA, Cerra F.B., Dellinger RP, Fein AM, Knaus WA, Schein R.M., Sibbald WJ. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
21. Cockcroft DW, Gault MH 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
22. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing. Twenty-fourth informational supplement. Document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Satlin MJ, Calfee DP, Chen L, Fauntleroy K.A., Wilson SJ, Jenkins SG, Feldman EJ, Roboz G.J., Shore TB, Helfgott DC, Soave R, Kreiswirth B.N., Walsh TJ. 2013. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54:799-806. http://dx.doi.org/10.3109/10428194.2012.723210.
24. Satlin MJ, Cohen N, Ma K.C., Gedrimaite Z., Soave R, Walsh TJ, Seo S. 2014. Prevalence, risk factors, and outcomes of bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies, abstr 434. Annu Meet Infect Dis Soc Am, ID Week, Philadelphia, PA. https://idsa.confex.com/idsa/2014/webprogram/Paper47661.html.
25. Oliveira MS, Prado GV, Costa S.F., Grinbaum RS, Levin AS. 2009. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65:431-434. http://dx.doi.org/10.1016/j.diagmicrobio.2009.07.018.
26. Tuon FF, Rigatto MH, Lopes C.K., Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43:349-352. http://dx.doi.org/10.1016/j.ijantimicag.2013.12.002.
27. Rigatto MH, Behle TF, Falci D.R., Freitas T., Lopes NT, Nunes M, Costa LW, Zavascki AP 2015. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70:1552-1557. http://dx.doi.org/10.1093/jac/dku561.
28. Abdelraouf K, Chang KT, Yin T, Hu M., Tam VH. 2014. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 58:4200-4202. http://dx.doi.org/10.1128/AAC.02557-14.
29. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P., Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300-1303. http://dx.doi.org/10.1093/cid/cit453.
30. Kubin CJ, Ellman TM, Phadke V, Haynes L.J., Calfee DP, Yin MT. 2012. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65:80-87. http://dx.doi.org/10.1016/j.jinf.2012.01.015.
31. Phe K, Lee Y, McDaneld P.M., Prasad N., Yin T, Figueroa DA, Musick W.L., Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:2740-2746. http://dx.doi.org/10.1128/AAC.02476-13.